Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | CCR6 | P51684 | 1/20 | 0.43 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27168312 | 0.86 | CCR6 (0.47) | ALDH1A1CCR6PAX8ABCB1MAPT | |
| SCHEMBL801192 | 0.85 | CCR6 (0.54) | ALDH1A1CCR6PAX8MAPTHPGD | |
| SCHEMBL7153018 | 0.85 | ALDH1A1 (0.40) | ALDH1A1CCR6PAX8ABCB1MAPT | |
| SCHEMBL2197305 | 0.85 | ALDH1A1 (0.47) | ALDH1A1ABCB1MAPTHPGDMAPK1 | |
| SCHEMBL4692471 | 0.81 | ALDH1A1 (0.54) | ALDH1A1CCR6PAX8ABCB1MAPT | |
| SCHEMBL11298253 | 0.80 | ALDH1A1 (0.51) | ALDH1A1CCR6PAX8MAPTHPGD | |
| SCHEMBL2011988 | 0.79 | ALDH1A1 (0.49) | ALDH1A1CCR6PAX8ABCB1MAPT | |
| SCHEMBL2787581 | 0.78 | CCR6 (0.50) | ALDH1A1CCR6PAX8MAPTHPGD | |
| SCHEMBL11860596 | 0.78 | ALDH1A1 (0.53) | ALDH1A1CCR6PAX8ABCB1MAPT | |
| SCHEMBL7282074 | 0.78 | CCR6 (0.48) | ALDH1A1CCR6PAX8ABCB1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12049465-B2 | Tricyclic compounds and their use as phosphodiesterase inhibitors | PFIZER INC. (US) | 2024-07-30 | — | — | US | disclosed |
| US-20230146535-A1 | TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | PFIZER INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230146535-A1 | TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | PFIZER INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230146535-A1 | TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | PFIZER INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230002386-A1 | TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | PFIZER INC. (US) | 2023-01-05 | — | — | US | disclosed |
| US-20230002386-A1 | TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | PFIZER INC. (US) | 2023-01-05 | — | — | US | disclosed |
| US-11472805-B2 | Tricyclic compounds and their use as phosphodiesterase inhibitors | PFIZER, INC. (US) | 2022-10-18 | — | — | US | disclosed |
| EP-3766885-B1 | TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | PFIZER (US) | 2022-05-25 | — | — | EP | disclosed |
| EP-3766885-B1 | TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | PFIZER (US) | 2022-05-25 | — | — | EP | disclosed |
| EP-3766885-A1 | TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | Pfizer Inc (US) | 2021-01-20 | — | — | EP | disclosed |
| US-20190263816-A1 | Tricyclic Compounds And Their Use As Phosphodiesterase Inhibitors | PFIZER INC. (US) | 2019-08-29 | — | — | US | disclosed |
| EP-3310784-A1 | TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | Pfizer Inc (US) | 2018-04-25 | — | — | EP | disclosed |
| WO-2016203347-A1 | TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | PFIZER INC. (US) | 2016-12-22 | — | — | WO | disclosed |
| WO-2016203347-A1 | TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | PFIZER INC. (US) | 2016-12-22 | — | — | WO | disclosed |
| EP-1677599-A4 | HYDROXY PYRIDOPYRROLOPYRAZINE DIONE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO INC (US) | 2008-10-22 | — | — | EP | disclosed |
| US-7435735-B2 | Hydroxy pyridopyrrolopyrazine dione compounds useful as HIV integrase inhibitors | MERCK & CO., INC. (US) | 2008-10-14 | — | — | US | disclosed |
| US-20070093496-A1 | Hydroxy pyridopyrrolopyrazine dione compounds useful as hiv integrase inhibitors | MERCK SHARP & DOHME CORP. | 2007-04-26 | — | — | US | disclosed |
| US-20070093496-A1 | Hydroxy pyridopyrrolopyrazine dione compounds useful as hiv integrase inhibitors | MERCK SHARP & DOHME CORP. | 2007-04-26 | — | — | US | disclosed |
| EP-1677599-A1 | HYDROXY PYRIDOPYRROLOPYRAZINE DIONE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS | Merck & Co., Inc. (US) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005041664-A1 | HYDROXY PYRIDOPYRROLOPYRAZINE DIONE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12049465-B2 | Tricyclic compounds and their use as phosphodiesterase inhibitors | PDE3B, PDE3A, PDE5A | ALDH1A1 972/4885CCR6 3090/4885PAX8 4752/4885 |
| US-20230146535-A1 | TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | PDE3B, PDE3A, PDE5A | ALDH1A1 972/4885CCR6 3090/4885PAX8 4752/4885 |
| US-11472805-B2 | Tricyclic compounds and their use as phosphodiesterase inhibitors | PDE3B, PDE3A, PDE5A | ALDH1A1 972/4885CCR6 3090/4885PAX8 4752/4885 |
| US-20190263816-A1 | Tricyclic Compounds And Their Use As Phosphodiesterase Inhibitors | PDE3B, PDE3A, PDE5A | ALDH1A1 972/4885CCR6 3090/4885PAX8 4752/4885 |
| US-20070093496-A1 | Hydroxy pyridopyrrolopyrazine dione compounds useful as hiv integrase inhibitors | DHPS, DPYD, TYMP | ALDH1A1 815/4885CCR6 2082/4885PAX8 2064/4885 |
| US-20230002386-A1 | TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | PDE3B, PDE3A, PDE5A | ALDH1A1 972/4885CCR6 3090/4885PAX8 4752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.